GlassScriptPhysician profile
Timothy C Zimmerman
NPI 1528177698
$3,046.02
in general payments reported to CMS, 2019-2025
30 companies · $99.33 in 2025
The $99.33 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $417 · 2021: $477 · 2022: $633 · 2023: $612 · 2024: $247 · 2025: $99.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $711.90 | 2019-2024 | Qulipta, Vraylar |
| Novo Nordisk INC | $517.63 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $387.17 | 2019-2025 | |
| Amgen INC. | $210.32 | 2019-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $183.50 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $175.11 | 2020-2023 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.05 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $108.83 | 2021-2023 | |
| Allergan, INC. | $71.99 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $62.87 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $53.00 | 2022-2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $46.24 | 2019-2023 | Myrbetriq |
| Sanofi-Aventis U.S. LLC | $43.94 | 2020-2021 | |
| Exact Sciences Corporation | $41.89 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.72 | 2021-2024 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $39.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.28 | 2022 | |
| Mylan Specialty L.P. | $17.45 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.39 | 2022 | |
| Merck Sharp & Dohme LLC | $16.96 | 2020 | |
| Sanofi Pasteur INC. | $16.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.89 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.55 | 2021 | |
| Philips North America LLC | $13.52 | 2022 | |
| Gilead Sciences, INC. | $13.49 | 2022 | |
| Genentech USA, INC. | $13.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.40 | 2022 | |
| Medtronic, INC. | $11.53 | 2021 | |
| Glaxosmithkline, LLC. | $11.21 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.